The human body possesses specific receptors, CB1 and CB2, designed to interact with cannabinoids. Mammals, including humans, produce their own cannabinoids, known as endocannabinoids (like anandamide and 2-AG), to maintain homeostasis.

These compounds activate natural receptors and help regulate appetite, mood, pain perception, memory, and concentration.

The ECS is an active and complex cell interaction network composed of endocannabinoids, a wide web of receptors (CB1 and CB2), and metabolic enzymes that break these compounds down.

Activation of cannabinoid receptors leads to inhibition of adenyl cyclase, which prevents the conversion of ATP to cyclic AMP (cAMP). Both CB1 and CB2 belong to the large G protein-coupled receptor family.

Found in the brain, central nervous system, lungs, muscles, vascular system, gastrointestinal tract, and reproductive organs.

Found in spleen, bones, and skin.

Found in immune system, liver, bone marrow, and pancreas.

Cannabis contains more than 500 biochemical compounds. There are flavonoids, terpenes, phytocannabinoids, and proteins, all with potential therapeutic applications.

Cannabidiol (CBD) is a non-psychoactive cannabinoid and tetrahydrocannabinol (THC) is a psychoactive cannabinoid found in cannabis. Both have been proven to have multiple benefits.

Endocannabinoid systems are a complex and integral part of every mammal's wellbeing. Cannabinoids are organic chemical compounds that work with other modulatory systems to activate receptors and regulate systems such as appetite, mood, pain perception, memory, and concentration.

Terpenes are organic compounds found in many plants and are responsible for distinct flavor and aroma. They play a key role in the entourage effect in conjunction with cannabinoids. Some terpenes support relaxation while others promote attention and alertness.

The cannabis plant contains more than 120 terpenes, with several common varieties highlighted below.

Exhibits sedative, antioxidant, anti-inflammatory, and analgesic effects, and may increase cell permeability. Commonly found in Indica strains.

Associated with increased serotonin levels and known for citrus-forward aroma dominant in many Sativa strains.

Recognized for sedative and relaxing effects and commonly found in Indica strains.

Has anti-inflammatory properties and strongly interacts with CB2 receptors. It is also a common terpene found in extracts because it survives extraction better than many monoterpenes.

CBD (cannabidiol) is a non-psychoactive compound from hemp that interacts with the ECS to support homeostasis. Many users report potential relief for chronic pain, anxiety, and insomnia, and ongoing studies continue to examine anti-inflammatory potential.

THCA (tetrahydrocannabinolic acid) is the precursor to THC in raw cannabis. Through decarboxylation (heating by smoking, vaporizing, or cooking), THCA loses a carboxyl group and converts into THC.

Delta-9 THC is the primary psychoactive compound in cannabis and is responsible for euphoric effects. It interacts with the ECS by binding to cannabinoid receptors in the brain and central nervous system.

CBG (cannabigerol) is often called the mother cannabinoid because it is a precursor to cannabinoids such as THC and CBD. As cannabis matures, CBG is converted through enzymatic processes, resulting in lower concentrations in mature plants.

CBG has gained attention for potential support with inflammation, pain, and nausea.

CBN (cannabinol) forms as THC oxidizes and degrades over time, especially with light and air exposure. While non-psychoactive, CBN is commonly associated with relaxation and sleep support.

Cannabis and humanity have had a close relationship since ancient times, with evidence dating back to around 10,000 BC in Chinese culture for food, textiles, and practical uses. Early medicinal references are attributed to Emperor Shennong in the 28th century BC.

2000 BCE: Emperor Shen-Nung recognized cannabis benefits for over 100 ailments in the Pen-ts'ao Ching.

1500 BCE: A wooden brazier was used to inhale cannabis smoke in China, likely as part of burial ceremonies.

800 BCE: The Atharva Veda mentions medicinal and spiritual uses of cannabis.

600 BCE: Ancient Scythians of Central Asia used early vapor bath techniques and gold bongs.

100 CE: Greco-Roman texts documented medical uses of cannabis.

1000 CE: The Anglo-Saxon Herbarium documented cannabis usage in Europe.

1025 CE: Persian scholar Avicenna acknowledged cannabis as medicine.

1500s: Cannabis came to the Americas via Spanish conquistadors and enslaved Africans.

1611: King James I decreed Jamestown colonists should grow hemp.

1798: Hashish spread in France after Napoleon's campaign in Egypt.

1830s: William O'Shaughnessy and Jacques-Joseph Moreau published research on medical cannabis.

1834: After Britain abolished slavery in colonies, Indian indentured servants are believed to have brought ganja to the Caribbean.

1906 - Pure Food and Drug Act: Required labeling of cannabis in over-the-counter remedies.

1900s-1920s: Recreational marijuana leaf use grew in the U.S. after Mexican immigration, alongside social stigma and anti-drug campaigns.

1930: Creation of the Federal Bureau of Narcotics (FBN); Harry J. Anslinger became first commissioner.

1930s: During the Great Depression, fear-driven narratives linked marijuana to crime; by 1931, 29 states had outlawed marijuana.

1932: Reefer Madness propaganda film was produced; narcotics depictions were broadly restricted in Hollywood.

1944: The La Guardia Report found marijuana less dangerous than commonly claimed and did not support links to violence or insanity.

1940s - Hemp for Victory: The USDA encouraged hemp farming for wartime materials; by 1943, U.S. farmers harvested about 375,000 acres.

1951-56: Federal laws introduced stricter mandatory sentences for drug offenses, including marijuana possession.

1960s: Marijuana use increased in counterculture; presidential reports suggested it did not inherently induce violence or lead to harder drugs.

1968: Creation of the Bureau of Narcotics and Dangerous Drugs.

1970: Congress repealed many mandatory minimums; marijuana was categorized separately from other narcotics in federal legislation; NORML was founded.

1972: The Shafer Commission recommended decriminalizing personal use, though President Nixon rejected the recommendation.

1973: DEA was created via merger of BNDD and ODALE.

1974: High Times was founded.

1976: Parent-led anti-marijuana movements expanded and influenced policy momentum in subsequent years.

1986: Anti-Drug Abuse Act increased federal mandatory sentencing tied to drug quantities; later amendments introduced harsher repeat-offender penalties.

1989: President George H. W. Bush announced a renewed national War on Drugs.

1996: California Proposition 215 legalized medical marijuana for qualified patients, marking a major modern policy shift at the state level.

Historical information was gathered from PBS Frontline chronology materials.